Mostafa M. Elbadawi

Dr. Mostafa M. Elbadawi

Assistant Professor, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAhmed E. Elsawi
Ahmed E. Elsawi
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
HAHadia Almahli
Hadia Almahli
SGSimone Giovannuzzi
Simone Giovannuzzi
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna

22 September 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
TATarfah Al-Warhi
Tarfah Al-Warhi
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
ABAlessandro Bonardi
Alessandro Bonardi
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
Ahmed A. Al-KarmalawyAhmed A. Al-Karmalawy
Ahmed A. Al-Karmalawy
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
In this work, different series of benzothiazole-based sulphonamides 8a-c, 10, 12, 16a-b and carboxylic acids 14a-c were developed as novel SLC-0111 analogues with the goal of generating potent carbonic anhydrase (CA) inhibitors. The adopted strategy involved replacing the 4-fluorophenyl tail in SLC-0111 with a benzothiazole motif that attached to the ureido linker to produce compounds 8c and its regioisomers 8a-b. In addition, the ureido spacer was elongated by methylene or ethylene groups to afford the counterparts 10 and 12. In turn, the primary sulfamoyl zinc binding group (ZBG) was either substituted or replaced by carboxylic acid functionality in order to provide the secondary sulphonamide-based SLC-0111 analogues 16a-b, and the carboxylic acid derivatives 14a-c, respectively. All compounds (8a-c, 10, 12, 14a-c and 16a-b) were tested for their ability to inhibit CA isoforms CA I, II, IX and XII. Additionally, the in vitro anticancer properties of the developed CAIs were evaluated.

9 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
WWWenjie Wang
Wenjie Wang
KAKeli K. Agama
Keli K. Agama
YPYves Pommier
Yves Pommier
Manabu AbeManabu Abe
Manabu Abe

20 December 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
AEAmer Ali Abd El-Hafeez
Amer Ali Abd El-Hafeez
WSWarda R. Somaa
Warda R. Somaa
AAAmgad Albohy
Amgad Albohy
Manabu AbeManabu Abe
Manabu Abe
In this study, different assortments of 2-arylquinolines and 2,6-diarylquinolines have been developed. Recently, we have developed a new series of 6,7-dimethoxy-4-alkoxy-2-arylquinolines as Topoisomerase I (TOP1) inhibitors with potent anticancer activity. Utilising the SAR outputs from this study, we tried to enhance anticancer and TOP1 inhibitory activities. Though target quinolines demonstrated potent antiproliferative effect, specifically against colorectal cancer DLD-1 and HCT-116, they showed weak TOP1 inhibition which may be attributable to their non-coplanarity. Thereafter, screening against kinase panel revealed their dual inhibitory activity against EGFR and FAK. Quinolines 6f, 6h, 6i, and 20f were the most potent EGFR inhibitors (IC50s = 25.39, 20.15, 22.36, and 24.81 nM, respectively). Meanwhile, quinolines 6f, 6h, 6i, 16d, and 20f exerted the best FAK inhibition (IC50s = 22.68, 14.25, 18.36, 17.36, and 15.36 nM, respectively). Finally, molecular modelling was employed to justify the promising EGFR/FAK inhibition. The study outcomes afforded the first reported quinolines with potent EGFR/FAK dual inhibition. Graphical Abstract

7 January 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
MTMohammed S. Taghour
Mohammed S. Taghour
TATarfah Al-Warhi
Tarfah Al-Warhi
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
Different 2,4-thiazolidinedione-tethered coumarins 5a–b, 10a–n and 11a–d were synthesised and evaluated for their inhibitory action against the cancer-associated hCAs IX and XII, as well as the physiologically dominant hCAs I and II to explore their selectivity. Un-substituted phenyl-bearing coumarins 10a, 10 h, and 2-thienyl/furyl-bearing coumarins 11a–c exhibited the best hCA IX (KIs between 0.48 and 0.93 µM) and hCA XII (KIs between 0.44 and 1.1 µM) inhibitory actions. Interestingly, none of the coumarins had any inhibitory effect on the off-target hCA I and II isoforms. The sub-micromolar compounds from the biochemical assay, coumarins 10a, 10 h and 11a–c, were assessed in an in vitro antiproliferative assay, and then the most potent antiproliferative agent 11a was tested to explore its impact on the cell cycle phases and apoptosis in MCF-7 breast cancer cells to provide more insights into the anticancer activity of these compounds.

1 June 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
ANAlessio Nocentini
Alessio Nocentini
MAMahmoud F. Abo-Ashour
Mahmoud F. Abo-Ashour
Eslam B. ElkaeedEslam B. Elkaeed
Eslam B. Elkaeed
MAMohammad M. Al-Sanea
Mohammad M. Al-Sanea